• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

The Trendy Topicals — Growth Factors, Exosomes, Peptides, NAD, PDRN, and the Rest

Growth Factors, Exosomes, Peptides, NAD, PDRN, and the Rest. What Does the Evidence Actually Say?

A new category of topical ingredient arrives in aesthetic medicine approximately every eighteen months, trailing impressive science and impressive marketing in roughly equal measure. Here is an honest attempt to separate the two.

The question that precedes all others

Before examining any topical ingredient on its own terms, there is a prior question that the industry consistently fails to ask loudly enough. Does it penetrate the skin in a biologically active form, in sufficient concentration, to reach the tissue where it is supposed to act?

We established in the companion piece that the stratum is a selective membrane. Molecules larger than approximately 500 Daltons cannot penetrate it easily under normal conditions.

The optimal characteristics of a topically delivered active ingredient i.e. low molecular weight, moderate lipophilicity and aqueous solubility are met by a relatively small proportion of the ingredients being as advanced topical therapies.

For the remainder, the question of penetration is not a minor technical detail. It is the central clinical question, and the one most conspicuously absent from product marketing.

With that question established as the lens through which everything that follows should be read, here is an honest assessment of the principal trendy topical categories.

Growth factors

Growth factors such as epidermal growth factor (EGF), transforming growth factor beta (TGF-beta), growth factor (FGF), and others are endogenous signalling proteins that regulate cell proliferation, differentiation, collagen synthesis, and wound healing. Their biological relevance to skin ageing is . The is whether they can be delivered effectively through a formulation.

Several studies indicate that topically applied growth factors and cytokines have been clinically shown to promote skin rejuvenation; however, their large molecular size, generally than 15,000 Daltons, limits their ability to penetrate the tightly packed stratum corneum. Molecules larger than 500 Daltons generally cannot easily penetrate the stratum corneum to reach the viable keratinocytes in the stratum basale

EGF, at approximately 6,000 Daltons, is considerably smaller than most growth factors and is therefore the most studied and most plausible candidate for topical delivery. The greatest efficiency of EGF was obtained intradermally, with a greater reduction of rhytids, folds, and a longer response over time. It may be possible to improve topical penetration by chemical modification with molecules or by facilitating diffusion through compromised skin, for after microneedling or laser resurfacing

The clinical implication is important: growth factor products may have some surface-level effect on in the upper epidermis, and post-procedural application following barrier disruption is a more defensible delivery strategy than standard topical application to intact skin.

A systematic review of twenty-three different topical growth factor preparations found evidence of clinical benefit in skin rejuvenation, but noted that study quality was variable and that the majority of preparations were evaluated in studies of relatively short duration. The mechanism is plausible, the evidence is real but modest, and the penetration remains only answered

Peptides

Peptides are short chains of amino acids, smaller and more structurally flexible than intact growth factor proteins, that act as signalling molecules, stimulating fibroblast activity, collagen synthesis, or muscle relaxation depending on their specific sequence.

Their smaller molecular size makes barrier penetration considerably more achievable than for larger proteins, and the peptide evidence base is correspondingly more developed.

Topical exosome and peptide therapies have shown promise in early trials, but neither is FDA approved. Use of topical products unique considerations for methods of drug delivery due to difficulty penetrating the skin barrier, meaning active in topical medications can be less effective than in other methods of drug delivery.

Signal peptides such as palmitoyl pentapeptide (Matrixyl) and its derivatives have a reasonable body of in vitro and clinical evidence supporting their collagen-stimulating effects. Neurotransmitter-inhibiting peptides, which claim to reduce the depth of expression lines by interfering with acetylcholine release at the neuromuscular junction, are mechanistically plausible but clinically considerably less potent than botulinum toxin, which should perhaps be stated more clearly in the marketing. The overall peptide picture is one of real but modest efficacy, significant formulation dependence, and a tendency for the marketing to what the evidence supports

Exosomes

Exosomes are nanoscale extracellular vesicles — typically 30 to 150 nanometres in diameter — secreted by cells and carrying a cargo of proteins, lipids, micro-RNAs, and signalling molecules. Their biology is genuinely fascinating. As mediators of intercellular communication, they play important roles in tissue repair, immune modulation, and cellular regeneration. The injectable exosome evidence, particularly in the context of wound healing and post-procedure recovery, is developing rapidly and with genuine scientific credibility.

The topical story is considerably more complicated. Exosomes are nanoscale and therefore theoretically capable of penetrating the stratum corneum through intercellular routes — but whether they do so in quantities to exert a meaningful effect on dermal fibroblasts, whether they remain biologically active after the manufacturing and formulation process, and whether the cell source and preparation method produce a standardised and reproducible biological entity, are questions the clinical literature has not yet answered satisfactorily.

The evidence base for topical exosomes remains early-stage and observational.

It is also worth noting — and we do so with a raised eyebrow rather than a sledgehammer — that one prominent in this category proudly carries the prefix "EXO" in its name. On reflection, that designation applies equally to every product ever applied to the surface of the skin. The word is doing marketing work, not scientific work.

A case study in honest complexity — Medik8 EXO-PDRN Prismatic+

Medik8 are a company we have considerable for. Their team is serious, their formulation standards are generally above industry average, and their willingness to engage with the distinguishes them from most of the cosmeceutical market. The recent acquisition by L'Oreal is a separate and somewhat melancholy observation.

Their EXO-PDRN Prismatic+ product, designed for post-microneedling application is worth examining in some detail precisely because it represents the category at its most scientifically credible.

The product contains several active ingredients, each of which merits individual assessment

A "Prismatic PDRN" described as a vegan, stable tetrahedral structure addresses the traditional sourcing around salmon-derived PDRN and claims structural optimisation for penetration. The tetrahedral DNA nanoparticle concept has genuine scientific grounding in drug delivery research; whether this formulation achieves meaningful dermal penetration through post-microneedling channels, before those channels close, typically within thirty to sixty minutes, is a question the marketing does not answer and the literature for this specific does not yet address.

The "GF MiniProtein" and "Expression Line MiniProtein" are proprietary complexes, the former likely a collagen-stimulating signal peptide, the latter suggesting something in the acetyl hexapeptide family. The smaller molecular size of purpose-designed peptides makes more achievable, and the post-microneedling delivery context is the most defensible application window for these ingredients.

The "Triple Exosome Complex, up to 50 billion exosomes per tube" raises the penetration and standardisation questions discussed above. The number is impressive; its clinical significance depends on factors the product information does not specify. The ATP precursor, almost certainly a NAD or NMN precursor addresses cellular energy metabolism; the topical evidence for this application remains thin.

The overall picture is of a thoughtfully formulated product with a scientifically plausible rationale, delivered in a context, post-microneedling, that represents the most defensible window for enhanced penetration of larger molecules. The gap between that and the clinical evidence for this specific combination in this specific delivery context is real, but it is a smaller gap than for most products in this category. Medik8 are operating at the credible end of a market that has a great deal of occupying the other end.

PDRN as a topical

We have written elsewhere about PDRN and as injectable biostimulators, where the evidence base is considerably more developed. As a topical ingredient, the picture is more speculative. PDRN molecules, in the range of 50 to 1,500 kilodaltons, are considerably larger than the 500 Dalton threshold for comfortable stratum corneum penetration. Post-procedural application following disruption represents the most scientifically defensible route of topical delivery, which is the context in which the Medik8 product is positioned.

NAD and its precursors

Nicotinamide adenine dinucleotide (NAD) and its precursors, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), have attracted considerable attention in the longevity and anti-ageing space based on their role in energy metabolism and DNA repair. The systemic evidence for NAD precursor supplementation in skin and overall ageing is genuinely interesting. The topical is considerably thinner. Whether topically applied NAD precursors reach mitochondria in viable keratinocytes in clinically meaningful concentrations, given the and the metabolic complexity of the conversion pathway, is not established to the standard the marketing implies. It is an area to watch with interest rather than one to invest heavily in on current evidence.

Bakuchiol — the "natural retinol alternative"

Bakuchiol is a plant-derived extracted from the seeds of Psoralea corylifolia, marketed extensively as a gentler, natural alternative to retinol and occasionally as ‘equivalent’ to it in efficacy. The evidence is more nuanced than either the enthusiasts or the sceptics tend to acknowledge.

A systematic review of fifteen human clinical trials using bakuchiol found that twelve trials were unblinded, open-label trials without a control group, and ten trials used bakuchiol in combination therapy rather than as a standalone ingredient.

That is a significant methodological limitation that should temper the confidence with which bakuchiol is described as a proven retinol equivalent. What the evidence does support is that bakuchiol has genuine antioxidant and anti-inflammatory properties, some collagen-stimulating activity in vitro, and a better tolerability profile than retinoids.

Bakuchiol is a retinol alternative with anti-ageing, antibacterial, and anti-inflammatory properties, though additional studies are warranted to better understand its applications in dermatology. 

The honest clinical positioning is: a useful, well-tolerated ingredient with real but modest anti-ageing activity, for patients who cannot tolerate retinoids rather than as a replacement for patients who can. Describing it as equivalent to retinol in efficacy is not currently supported by the evidence, and doing so does a disservice to patients who might otherwise work through the retinoid adaptation period and access a considerably more powerful active ingredient.

Stem cell extracts

A brief word on stem cell extracts — plant or human — which appear in an increasing number of premium products. Plant stem cells are irrelevant to human skin . Human stem cell extracts raise questions about standardisation, stability, and whether any biologically active material the formulation in a form that can penetrate the barrier and reach target cells. We are aware of no peer-reviewed evidence that stem cell extracts in topical skincare produce clinically through the mechanisms claimed. This is perhaps the category where marketing has most outpaced science.

The framework for evaluation

Having examined the principal trendy topical categories, the following framework emerges for evaluating any new ingredient as it arrives:

Does it penetrate the barrier in the concentrations in the formulation

Is it biologically stable after the manufacturing and formulation process?

Is the evidence base of manufacturer funding?

Are the studies adequately controlled, blinded, and of sufficient duration.

Does the claimed mechanism correspond to a plausible biological reality in the tissue it is supposed to reach?

These are the questions we established in our post, and they apply here with full force. The ingredients examined in this piece span a wide range of credibility from genuinely promising and scientifically coherent to mechanistically and poorly evidenced. What they share, almost without exception, is a marketing presentation that does not adequately distinguish in vitro data, animal data, early clinical observations, and established clinical